International Society of Sports Nutrition Position Stand: Probiotics
- Open Access
- 01.12.2019
- Review
Abstract
Introduction
Concept | Definition |
Probiotics | Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host [1]. |
Prebiotic | A substrate that is selectively utilized by host microorganisms conferring a health benefit on the host [2]. |
Synbiotics | A synbiotic product beneficially affects the host in improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract by selectively stimulating the growth and/or activating the metabolism of one or a limited number of health-promoting bacteria [3]. |
Postbiotics | Postbiotics are bioactive components produced by beneficial bacteria (through a natural fermentation process) which have biological activity in the gut (e.g. short-chain fatty acids) [4]. |
Immunobiotics | Inactivated probiotics (e.g. heat-killed), in which the dead cells maintain their immune benefit. |
Gut | The gastrointestinal tract is a long tube that starts in the mouth and ends at the anus. Its main function is to process food. Approximately 70% of antibody producing cells are is located in the digestive system. |
Microbiota vs. Microbiome | The gut microbiota is a diverse ecosystem consisting of bacteria, archaea, viruses, protists and fungal communities (mycobiome) living in the human gut. Microbiome refers to the collection of genomes from all microorganisms in a particular environment |
Transient vs. Resident Strain | Supplementary probiotics are transient strains. There is currently no evidence that supplementary probiotics can permanently colonize in the gut as resident strains resist colonization by transient strains. Transient probiotics strains may have numerous beneficial health effects by positively interacting with the immune system or stimulating growth of beneficial resident strains. |
Alpha-Diversity | Represents the number of species and the proportion in which each species is represented in the microbiota. A high alpha diversity is present when there is a high number of species and their quantities are alike. |
Beta-Diversity | Beta-diversity broadly reflects the species composition diversity between regional and local sites. The beta diversity measures the turnover of species between two regions in terms of gain or loss of species |
Classes of probiotics | Definition |
Lactic acid bacteria (LAB) | Nonpathogenic, nontoxigenic, Gram-positive, fermentative bacteria that are associated with the production of lactic acid from carbohydrates. LAB grow anaerobically, but unlike other anaerobes, most can grow in the presence of oxygen. Examples include Lactobacillus (ssp. acidophilus, fermentum, plantarum, rhamnosus, casei, reuteri, gasseri), Streptococcus (e.g. salivarius, thermophilus) and Lactococcus. |
Bifidobacteria | Bifidobacteria are among the first microbes to colonize the human gastrointestinal tract. Examples include Bifidobacterium bifidum, longum, animalis, and breve. Bifidobacteria are not LAB. They are, however lactic acid producing bacteria (but through a very different metabolic pathway). |
Spore-forming bacteria | Soil-based probiotics, also referred to endospores, are the dormant form of bacteria that are highly resistant to physical and chemical influences. Upon ingestion, these spores have a high survival rate through the stomach and germinate in the small intestine. Examples include Bacillus (e.g. coagulans, subtilis). Spore forming bacteria are not necessarily of soil origin. They can also be found in fermented foods. |
Yeast | Examples include Saccharomyces boulardii. |
Taxonomic level | Name |
|---|---|
Domain | Bacteria |
Phylum | Firmicutes |
Class | Bacilli |
Order | Lactobacillales |
Family | Lactobacillaceae |
Genus | Lactobacillus |
Species | Lactobacillus rhamnosus |
Strain | Lactobacillus rhamnosus GG |
Role of diet and exercise on an athlete’s gut microbiome
Key Points 1 – Role of diet and exercise on an athlete’s gut microbiome. | |
• Active individuals appear to display a higher abundance of health-promoting bacterial species and increased microbiota diversity. | |
• Body composition and physical activity are positively correlated with several bacterial populations. | |
• Overall exercise can enrich the microbiota diversity, increase the Bacteroidetes-Firmicutes ratio, stimulate the proliferation of bacteria which can modulate mucosal immunity, and improve barrier functions. | |
• Diet is an established modulator of gut microbiota composition and activity, with marked changes in microbiota composition evident within 24 h of a dietary modification. | |
• Protein intake appears to be a strong modulator of microbiota diversity, with whey protein showing some potential benefits that need further study in humans. | |
• Higher intakes of carbohydrate and dietary fiber in athletes appear to be associated with increased abundance of Prevotella. | |
• The specific effects of fat on the gut microbiota is difficult to isolate, however, the types of fats consumed appear to be important. |
Benefits of probiotic supplementation in athletes
Reference | Subject group | Sex and age (M ± SD) | Supplementation | Treatment duration | Exercise | Diet | Performance Benefit | Immune or GI Benefit |
|---|---|---|---|---|---|---|---|---|
Clancy et al. (2006) [53] | Healthy recreational athletes (n = 18), Fatigued recreational athletes (n = 9) | 11 M / 7 F 16–37 y 6 M / 3 F 17–40 y | L. acidophilus (LAFTI®L10), capsules, 2 × 1010 CFU Daily | 4 weeks | Not reported | Not reported | Not assessed | T cell deficit was reversed (increased secretion of IFNƴ from T cells) following probiotic supplementation |
Moreira et al. (2007) [54] | Non-elite Marathon runners (n = 141) | 62 M / 8 F in treatment group 39 ± 9 y | L. rhamnosus GG (LGG), milk-based drink, 4 × 1010 CFU Daily | 12 weeks | Running During pollen season & 2003 Helsinki City Marathon | Subjects instructed to refrain from eating food containing probiotics | Not assessed | No effects on symptoms of atopy or asthma |
Kekkonen et al. (2007)* [55] | Non-elite Marathon runners (n = 141) | 62 M / 8 F in treatment group 39 ± 9 y | L. rhamnosus GG (LGG), milk-based drink, 4 × 1010 CFU Daily | 12 weeks | Running During pollen season & 2003 Helsinki City Marathon | Subjects instructed to refrain from eating food containing probiotics | Not assessed | No effect on respiratory infections or GI episodes. Shortened GI stress post marathon |
Tiollier et al. (2007) [56] | French commando cadets (n = 47) | 47 M 21 ± 0.4 y | L. casei DN- 1 14 00 1, milk-based drink during training (dose not indicated) Daily | 3 weeks | Military training for 3 weeks followed by a 5-day combat course | Military ration. No fermented dairy products | Not assessed | No effect on respiratory tract infections |
Cox et al. (2010) [57] | Elite male distance runners (n = 20) | 20 M 27.3 ± 6.4 y | 1.2 × 1010 CFU L. fermentum VRI-003 (PCC) Daily | 16 weeks | Running (winter training) | Not reported | No changes in running performance | Significant reduction in respiratory episodes and severity |
Martarelli et al. (2011) [58] | Amateur cyclists (n = 24) | 24 M 32.03 ± 6.12 y | L. rhamnosus IMC 501®, L. paracasei IMC 502® 1 × 109 CFU Daily | 4 weeks | Intense physical activity | Diets proportionally equivalent in macro and micronutrient quantity, containing 100% of the RDA for all nutrients | Not assessed | Reduced exercise induced oxidative stress |
Recreationally active endurance athletes (n = 84) | 54 M / 30 F 27.0 ± 11.6 y | L. casei Shirota (LcS), 6.5 × 109 CFU 2x daily | 16 weeks | Running (winter training, normal training load) | Consumption of supplements, additional probiotics, or any fermented dairy products were not permitted during the study period | Not assessed | Significant reduction in frequency of URTI | |
West et al. (2011) [61] | Competitive cyclists (n = 80) | 64 M / 35 F 35 ± 9 and 36 ± 9 y | L. fermentum (PCC®) 1 × 109 CFU Daily | 11 weeks | Cycling (winter training, normal training load) | Subjects were asked to maintain a normal diet and refrain from eating probiotic or prebiotic enriched foods or supplements | No effect on peak power or VO2 max | Significant reduction in URTI (duration and severity) in males. No effect in females |
Välimäki et al. (2012) [62] | Marathon runners Placebo (n = 58), Probiotic (n = 61) | 105 M / 14 F 40 (23–69) y 40 (22–58) y | L. rhamnosus GG (LGG), 4 × 1010 CFU Daily | 12 weeks | Running training; marathon run | Instructed to refrain from eating food containing probiotics and advised to follow normal dietary habits | Not assessed | No effects on serum LDL or antioxidant levels |
Lamprecht et al. (2012) [63] | Endurance trained men (triathletes, runners, cyclists) (n = 23) | 23 M 37.6 ± 4.7 y | Multispecies probiotic (B. bifidum W23, B. lactis W51, E. faecium W54, L. acidophilus W22, L. brevis W63, and L. lactis W58, 1 × 1010 CFU Daily | 14 weeks | Normal training load | 7-dayfood record. Instructed to maintain their habitual diet | No effect on VO2 max, maximum performance | Significant reduction in Zonulin (marker of gut permeability) |
Gleeson et al. (2012) [64] | Highly active individuals (n = 66) | 28 M / 38 W 23.9 ± 4.7 y | L. salivarious, 2 × 1010 CFU Daily | 16 weeks | Endurance-based physical activities (spring training) | Consumption of supplements, additional probiotics, or any fermented dairy products was not permitted | Not assessed | No effect on frequency, severity and duration of upper respiratory tract infections |
Grobbelaar et al. (2012) [65] | Moderately active individuals (n = 50) | 50 M 18–30 y | Bifidobacterium and Lactobacillus strains (dose not indicated) Daily | 6 weeks | Moderately active as defined by ACSM and CDC | Nutritional supplementation prohibited | Not assessed | No significant increases in performance related blood markers |
West et al. (2012) [66] | Active individuals (n = 22) | 22 M 33.9 ± 6.5 y | Multi-strain probiotic (4.6 × 108 CFU L. paracasei subs paracasei (L. casei 431®), 6 × 108 CFU B. animalis ssp. lactis (BB-12®), 4.6 × 108 CFU L. acidophilus LA-5, 4.6 × 108 CFU L. rhamnosus GG Daily | 3 weeks | Recreational cycling | Not reported | Not assessed | No effect on measures of systemic or mucosal immunity including gut permeability |
Salarkia et al. (2013) [44] | Adolescent endurance swimmer (n = 46) | 46 F 13.8 ± 1.8 y | Multi-strain probiotic yoghurt (L. acidophilus SPP, L. delbrueckii bulgaricus, B. bifidum, and S. salivarus thermnophilus) 4 × 1010 CFU Daily | 8 weeks | Swimming | Advised to refrain from other probiotic products | Significant improvement in VO2 max. No effect on swim times | Significant reduction in respiratory and ear infections. No effect on GI episodes |
Charlesson et al. (2013) Abstract of 2012 IJSNEM Confer. | Male athletes (n = 8) (travelling to high risk travelers’ diarrhea countries) | 8 M Age not reported | L. acidophilus, B. lactis, L. rhamnosus (dose not indicated) Daily | 8 weeks | Normal training | Not reported | Not assessed | No effect on travelers’ diarrhea (TD). 50% of all athletes reported TD symptoms |
Sashihara et al. (2013) [67] | University-student athletes (n = 44) | 44 M Grp-1: 19.8 ± 0.9 y Grp-2: 19.9 ± 0.9 y | Grp-1: L. gasseri OLL2809 1 × 109 CFU. Grp-2: alpha-lactalbumin 900 mg +: L. gasseri OLL2809 1 × 109 CFU 3x daily | 4 weeks | Normal training load | Not reported | No improvement in 1 h of cycle ergometer exercise performance | Prevented reduced natural killer cell activity due to strenuous exercise and elevated mood from a depressed state (POMS) |
West et al. (2014) [68] | Active individuals (n = 465) | 241 M / 224 F 35 ± 12 y / 36 ± 12 y | B. animalis subsp. lactis BI-04 2 × 1010 CFU, or L. acidophilus NCFM and B. animalis subsp. lactis BI-07 5 × 109 CFU Daily | 150 days (21.42 weeks) | Normal activity load (approx. 6 h per week) | Refrain from consumption of non-study probiotic or prebiotic supplements or foods during the study. | Not assessed | BI-04 reduced upper respiratory tract infection frequency. BI-07 + LA NCFM showed no effect. Probiotic treatments delayed URTI ~ 0.8 months |
Haywood et al. (2014) [69] | Highly-trained rugby union players (n = 30) | 30 M 24.7 ± 3.6 y | L. gasseri 2.6 × 109 CFU, B. bifidum 0.2 × 109, and B. longum 0.2 × 109 CFU Daily | 4 weeks | Normal training load (during the winter months) | Asked to maintain a normal diet and refrain from consuming probiotic and prebiotic enriched foods or supplements | Not assessed | Significant reduction in episodes of illness. No effect on illness severity |
Shing et al. (2014) [46] | Runners (n = 10) | 10 M 27 ± 2 y | Multispecies probiotic (L. acidophilus, L. rhamnosus, L. casei, L. plantarum, L. fermentum, B. lactis, B. breve, B. bifidum, and S. thermophilus) 4.5 × 1010 CFU Daily | 4 weeks | Normal training load | Provided with a high glycemic index, low sucrose diet for the 26 h prior to each time to-fatigue run. | Significant increase in run time to fatigue in the heat | No effects on inflammation or GI markers |
Aghaee et al. (2014) [70] Abstract | Athletes (n = 16) | 16 M 19–25 y | Probiotic (type and dose not indicated) Daily | 30 days | Normal training load | Not reported | Not assessed | Probiotic treatment significantly increased monocyte levels in comparison to placebo control |
Georges et al. (2014) PILOT [71] | Resistance-trained individuals (n = 10) | 10 M 22.0 ± 2.4 y | B. coagulans GBI-30, 6086 (BC30), 5 × 108 CFU plus 20 g of casein 2x daily | 8 weeks | Periodized resistance training (4x per week) | Macronutrients were controlled to 50% carbohydrate, 25% protein, and 25% fat between groups. | Trend to increase vertical jump power (not significant). | Not assessed |
Narimani-Rad et al. (2014) [72] | Professional bodybuilding athletes (n = 14) | 14 M 20–55 y | Multi-strain probiotic (L. casei 5.1 × 109 CFU/g, L. acidophilus 2 × 109 CFU/g, L. C. 5.1 × 109 CFU/g, L. bulgaricus 2 × 108 CFU/g, B. breve 2 × 1010 CFU/g, B. longum 7 × 107 CFU/g, S. thermophilus 5.1 × 109 CFU/g) Daily | 30 days | Normal training load | Not reported | Not assessed | Stimulated thyroid activity. Significant increase in T4 and significant decrease TSH levels. No significant difference in T3 levels |
Muhamad & Gleeson (2014) [73] | Active University students (n = 11) | 11 (sex not reported) 22 ± 1 y | 14 strain probiotic (L. acidophilus, L. delbrueckii ssp. bulgaricus, L. lactis ssp. lactis, L. casei, L. helveticus, L. plantarum, L. rhamnosus, L. salivarius ssp. salivarius, B. breve, B. bifidum, B. infantis, B. longum, B. subtilis, and S. thermophilus.) 6 × 109 CFU Daily | 30 days | Not reported | Not reported | No significant change in rating of perceived exertion and HR | No significant change in salivary antimicrobial proteins (a measure of mucosal protection) |
Salehzadeh (2015) [45] | Endurance athletes (n = 30) | 30 M 21 y | 200 ml of probiotic yogurt drink S. thermophilus or L. delbrueckii ssp. bulgaricus 1 × 105 CFU/g Daily | 30 days | Intense aerobic training | Not reported | Significant increase in VO2 MAX and aerobic power | Significant decrease in serum CRP, significant increase in HDL |
O’Brien et al. (2015) [74] | Male and female runners (n = 67) | Not reported 18–24 y | Kefir beverage (probiotic strain and amount not indicated) 2x week | 15 weeks | Marathon training program | Not reported | No effect on 1.5 mile run test times | Attenuated increase in inflammation (serum CRP) |
Gill et al. (2016a) [75] | Endurance-trained runners (n = 8) | 8 M 26 ± 6 y | L. casei 10 × 1010 CFU Daily | 7 days | Running exercise in hot ambient temperature | Refrained from alcohol and caffeine for 72 h and exercise for 24 h before preliminary testing sessions and each experimental trial | No difference in exercise performance on a treadmill test and perception of effort | No improvement in salivary antimicrobial protein (mucosal immune protection) or cortisol status over placebo |
Gill et al. (2016b) [76] | Endurance-trained runners (n = 8) | 8 M 26 ± 6 y | L. casei 10 × 1010 CFU Daily | 7 days | Running exercise in hot ambient temperature | Consumption of other probiotics was prohibited outside the study protocol | Not reported | Did not prevent increases in external heat stress-induced circulatory endotoxin concentration or plasma cytokine profile compared with placebo |
Jäger et al. (2016) [42] | Recreationally-trained individuals (n = 29) | 29 M 21.5 ± 2.8 y | B. coagulans GBI-30, 6086 (BC30), 1 × 109 CFU plus 20 g of casein protein Daily | 2 weeks | Muscle-damaging single leg training bout | Subjects provided a standardized meal prior to exercise bout. Three-day dietary recalls were collected | Significantly increased recovery and decreased soreness. Non-significant trend to increase power | Not assessed |
Jäger et al. (2016) [43] | Resistance-trained men (n = 15) | 15 M 25 ± 4 y | B. breve BR03 5 × 109 live cells (AFU) & S. thermophilus FP4 5 × 109 live cells (AFU) Daily | 3 weeks | Normal training up until 72 h preceding muscle-damaging elbow flexor exercise challenge | Refrain from any nutritional supplements or ergogenic aids | Improved isometric average peak torque production and range-of-motion during acute recovery | Significant decrease in marker of inflammation (IL-6) |
Roberts et al. (2016) [77] | Recreational triathletes (n = 30) | 25 M / 5 F 35 ± 1 y | Multi-strain pro/prebiotic/antioxidant 30 × 109 CFU per day containing 10 × 109 CFU L. acidophilus CUL-60 (NCIMB 30157), 10 × 109 CFU L. acidophillus CUL-21 (NCIMB 30156), 9.5 × 109 CFU B. bifidum CUL-20 (NCIMB 30172) and 0.5 × 109 CFU B. animalis subsp. lactis CUL-34 (NCIMB 30153)/55.8 mg fructooligosaccharides/ 400 mg alpha-lipoic acid, 600 mg N-acetyl-carnitine Daily | 12 weeks | Progressive triathlon training program | Maintained habitual dietary intake. Required not to consume any other nutritional supplement | No significant difference in race times | Significant reduction in endotoxin levels |
Strasser et al. (2016) [78] | Trained athletes (n = 29) | 13 M / 16 F 26.7 ± 3.5 y | Multi-species probiotic (B. bifidum W23, B. lactis W51, E. faecium W54, L. acidophilus W22, L. brevis W63, and L. lactis W58) 1 × 1010 CFU/g Daily | 12 weeks | Winter training | Maintain normal diet and avoid anti-inflammatory drugs, antibiotics, additional probiotics and dietary supplements | Did not benefit athletic performance | Limited exercise-induced drops in tryptophan levels and reduced the incidence of URTI |
Michalickova et al. (2016) [79] | Elite athletes (badminton, triathlon, cycling, alpinism, karate, savate, kayak, judo, tennis and swimming) (n = 39) | 29 M / 10 F 23.15 ± 2.6 y | L. helveticus Lafti L10, 2 × 1010 CFU Daily | 14 weeks | Normal training load (during winter) | Subjects maintained normal diet and were asked to avoid fermented milk products and immunomodulatory supplements | No significant differences in exercise performance | Significant reduction in duration of URTI episodes and decreased symptoms in elite athletes |
Gleeson et al. (2016) [80] | College athletes (n = 243) | 142M / 101F 20.4 ± 0.2 y | Fermented milk beverage containing L. casei Shirota, 6.5 × 109 CFU 2x daily | 20 weeks | Normal training load | Supplements that might influence immune function and additional probiotics or fermented dairy were not permitted | Not assessed | Significant reduction in cytomegalovirus and Epstein Barr virus antibody titres, benefiting immune status |
Michalickova et al. (2017) | Elite athletes (badminton, triathlon, bicycling, athletics, karate, kayaking, and judo) (n = 30) | 24 M / 6 F 23.6 ± 1.9 y | L. helveticus Lafti L10, 2 × 1010 CFU Daily | 14 weeks | Normal training load (winter training) | Subjects maintained normal diet and were asked to avoid fermented milk products and immunomodulatory supplements | Not assessed | Supported humoral and mucosal immunity by preserving total salivary Immunoglobulin A level |
Gepner et al. (2017) | Soldiers from elite combat unit (n = 26) | 26 M 20.5 ± 0.8 y | B. coagulans GBI-30 (BC30) 1.0 × 109 CFU and HMB 3 g Daily | 40 days | Strenuous military training 40 days | No additional dietary supplements nor consumtion any androgens or other performance-enhancing drugs | Not assessed | Combined supplementation attenuated IL-6 and IL-10 response and maintained muscle integrity |
Marshall et al. (2017) [81] | Marathon competitors (n = 32) | 26 M / 6 F 23–53 y | PRO-grp: Multi-strain capsule; L. acidophilus CUL-60 10 × 109 CFU, and L. acidophillus CUL-21 (NCIMB 30156) 10 × 109 CFU), B. bifidum CUL-20 9.5 × 109 CFU and B. animalis subsp. lactis CUL-34 0.5 × 109 CFU, and 55.8 mg fructooligosaccharides. PGLn-grp: L. acidophilus CUL-60 (NCIMB 30157) 2 × 109 CFU, L. acidophilus CUL-21 (NCIMB 30156) 2 × 109, B. bifidum CUL-20 (NCIMB 30172) 0.5 × 109 CFU, B. animalis subsp. lactis CUL-34 (NCIMB 30153) 0.95 × 109 CFU, L. salivarius CUL61 (NCIMB 30211) 5 × 109 CFU, and each 5-g dose also contained 0.9 g L-glutamine. Daily | 12 weeks | Marathon training; Marathon race | Not permitted to consume any other commercial supplementation that conflicted with the study parameters | No difference in marathon time to completion compared to control group | No change in immuno-stimulatory heat shock protein (eHsp72) concentrations |
Toohey et al. (2018) [20] | Soccer and volleyball Division I college athletes (n = 23) | 23 F 19.6 ± 1.0 y | B. subtilis (DE111) 5 × 109 CFU Daily | 10 weeks | Offseason resistance training program | No dietary restrictions were placed on the athletes besides abstaining from other supplement use | No effect on physical performance parameters | Significant reduction in body fat percentage |
Brennan et al. (2018) [82] Abstract of 2018 ACSM Confer. | Endurance athletes (n = 7) | (sex not reported) 31 ± 6.1 y | L. salivarius (UCC118) (dose not indicated) Daily | 4 weeks | Not reported | Not reported | Not assessed | Exercise-induced intestinal hyperpermeability was attenuated |
Townsend et al. (2018) [83] | Division I Baseball Players (n = 25) | 25 M 20.1 ± 1.5 y | B. subtilis (DE111) 1 × 109 CFU Daily | 12 weeks | Offseason training | Three-day food logs collected on weeks 1, 9 and 12. | No effect on physical performance or body composition | TNF-α concentrations were significantly lower compared to placebo |
Antonio et al. (2018) [84] | Active men and women (n = 20) | 6 M/ 14 F 30 ± 8 y | B. breve BR03 5 × 109 CFU and S. thermophilus FP4 5 × 109 CFU Daily | 6 weeks | Normal training load (aerobic and/or resistance training) | Subjects were instructed to not alter their diet | No effect on body composition | Not assessed |
Huang et al. (2018) [85] | Healthy adults without professional athletic training (n = 16) | 16 M 20–40 y | L. plantarum TWK10 1 × 1011 CFU Daily | 6 weeks | Not reported | Normal diet maintained and no consumption of any other nutritional supplements | Improved endurance performance and blood glucose concentration in a maximal treadmill running test | Not assessed |
Carbuhn et al. (2018) [86] | Division I collegiate female swimmers (n = 17) | 17 F Age not reported | B. longum 35,624, 1 × 109 CFU Daily | 6 weeks | Offseason training | Three-day food logs collected at baseline and weeks 3 and 6. | No effect on aerobic/anaerobic swim time trials and force plate vertical jump | No effect on cytokine and gastrointestinal inflammatory markers and salivary IgA levels |
Huang et al. (2019) [87] | Healthy adult triathletes (n = 34) | Study 1: 18 M, 20.2 ± 0.7 y Study 2: 16 M, 22.3 ± 1.2 y | L. plantarum PS128 3 × 1010 CFU Daily | Study 1: 4 weeks Study 2: 3 weeks | Sprint triathlon (swimming 750 m, biking 20 km, running 5 km). | Before race: 595 kcal (24 g PRO, 16 g FAT, 90 g CHO). In race: 30–40 g CHO and 500–1000 ml water per hour. | Attenuated post-triathlon performance declines. No effect on body composition. | Reduced post-race inflammatory cytokines, reduced oxidative stress, increased plasma BCAA levels. |
Pugh et al. (2019) [88] | Health adult marathon runners (ran marathon race quicker than 5 h within the previous 2 years; n = 24) | 20 M / 4 F 34.8 ± 6.9 y | L. acidophilus (CUL60 and CUL21), B. bifidum (CUL20), B. animalis subs p. Lactis (CUL34) > 25 billion CFU daily in total, no information on individual strains | 4 weeks (pre-race) | Marathon race | Before race: standardized high CHO, low fiber diet. In race: 60 mL CHO gel with 200 mL (15 min before start, 40 min post and every 20 min for the remainder of the race. | No difference in race times. | GI symptom severity during the final third was significantly lower. |
Pumpa et al. (2019) [89] | Elite rugby union athletes (n = 19) | 19 M 27.0 ± 3.2 y | L. rhamnosus, L. casei, L. acidophilus, L. plantarum, L. fermentum, B. lactis, B. bifidum, S. thermophilus 120 billion CFU daily in total, no information on individual strains 500 mg S. boulardi (added during stage 3) | 17 weeks | 27-weeks, divided into three stages: 1) control period (10 weeks); 2) domestic competition (7 weeks); 3) international competition (10 weeks). | A national training camp and 3 domestic games (stage one), 6-weeks of domestic competition (stage two), and 8-weeks of international competition (stage three). | Not assessed | No effect on salivary Immunoglobulin A. Salivary cortisol increased. Increase in salivary alpha-amylase levels during stage 3. |
Vaisberg et al. (2019) [90] | Amateur marathon runners with previous history of post-race URTI (n = 42) | 42 M 39.5 ± 9.4 y | Fermented milk beverage containing L. casei Shirota, 4 × 1010 CFU Daily | 30 days (pre-race) | Marathon race | Unknown | Not assessed | Improved airway and systemic immune and inflammatory responses post-marathon. No significant effect on URTI. |
The effect of probiotic supplementation on performance
Key Points 2 – Probiotic Supplementation and Performance | |
• To date single-strain probiotic supplementation has produced a significant aerobic performance benefit in only one study. | |
• Supplementation with multi-strain probiotics has been reported to increase VO2 max, aerobic power, training load, and time to exhaustion in several studies, but more studies have not found such an effect. | |
• In response to muscle-damaging resistance exercise, probiotic supplementation (paired with protein) can expedite recovery and decrease soreness and other indices of skeletal muscle damage. | |
• The effect of probiotic supplementation on body composition has been mixed and requires further research. | |
• Probiotics supplementation as an ergogenic aid for performance enhancement requires further investigation and may be indirect via modulation of other systems. |
The effect of probiotic supplementation on the immune system
Key Points 3 – Effects of Probiotic Supplementation on Immune Function | |
• Athletes may compromise their immune status with high training loads (over-reaching, over-training) which can increase the risk of illness such as URTIs. | |
• Overall, the current body of evidence indicates small variable benefits of probiotics during intense training, particularly in endurance athletes, the cohort where the majority of studies are conducted. | |
• There is more evidence for the clinical effects of probiotics reducing the incidence URTI and related illness. | |
• Positive changes in circulating and salivary immune markers have been more variable and require further research to define more clearly. |
The effect of probiotic supplementation on GI tract health
Key Points 4 – Probiotic Supplementation and Gastrointestinal Health. | |
• GI problems often occur in endurance athletes and can impair the delivery of nutrients, cause GI symptoms and decrease performance. | |
• A small number of studies assessing GI benefit in athletes and physically active individuals have yielded mixed results with considerable variation in methodology, making comparison difficult. | |
• Positive results reported included decreases in concentrations of zonulin and endotoxin, intestinal hyperpermeability and duration of GI-symptom episodes. |
Mechanism of action
Support of the gut epithelial barrier
Adhesion to intestinal mucosa
Postbiotics
Modulation of the immune system
Improved nutrient absorption
Key Points 5 – Mechanisms of Action | |
• There are dozens of bacterial strains that can be considered as probiotics, particularly those that produce lactic acid. However, each strain is unique with respect to how it responds to and affects the host. | |
• The mechanisms underlying the beneficial effects of probiotics in athletes are largely unknown but are likely to be multifactorial. | |
• Consumption of some probiotic strains may improve intestinal barrier function by modulating tight junction permeability. However, the mechanisms by which probiotics enhance intestinal barrier function are not sufficiently studied. | |
• Adhesion of probiotics to the intestinal mucosa may be a mechanism for modulation of the immune system. Probiotics also cause alterations in intestinal mucins that prevent pathogen binding. | |
• Probiotics may support microbiota and postbiotic production which possess different functional properties including, but not limited to, antimicrobial, antioxidant, and immunomodulatory. | |
• Probiotics may enhance innate immunity by upregulating immunoglobulins, antimicrobial proteins, phagocytic activity, and natural killer cell activity, and also enhance acquired immunity by improving antigen presentation and function of T and B lymphocytes to neutralize pathogens and virally-infected cells. | |
• Probiotics can potentially modulate intestinal permeability and health of the cells of the gut lining improving nutrient absorption including minerals, peptides, and amino acids by decreasing inflammation and encouraging optimum development of the absorptive area of the villi. |
Safety and health
Key Points 6 – Safety and Health. | |
• Probiotics have been used safely in foods and dairy products for over a hundred years. | |
• Well-studied probiotic species include Bifidobacterium (ssp. adolescentis, animalis, bifidum, breve, and longum) and Lactobacillus (ssp. acidophilus, casei, fermentum, gasseri, johnsonii, reuteri, paracasei, plantarum, rhamnosus, and salivarius). | |
• Safety assessments should take into account the nature of the probiotic microbe, method of administration, level of exposure, health status of the recipients, and the underlying physiological functions the microbes are intended to perform. | |
• Four classes of possible side effects are commonly reported from probiotic use in vulnerable patient groups: systemic infections, detrimental metabolic effects, cytokine-mediated immunologic adverse events in susceptible individuals, and transfer of antibiotic resistance genes. | |
• The current body of research of probiotic supplementation for healthy athletes and physically active individuals suggests that they are safe for use. | |
• Caution is warranted for those with serious health conditions. In these instances, patients should consult with their health care practitioner before supplementing. | |
• Consumers are advised to supplement with probiotics strains and products within evidence-based dosages. |
Regulation
Type | Dosage range |
|---|---|
Lactobacillus (n = 35) | 1 × 109 – 10 × 1010 CFU |
Bifidobacterium (n = 18) | 7 × 107–9.5 × 109 CFU |
Streptococcus (n = 8) | 5 × 109–4.5 × 1010 CFU |
Bacillus (n = 5) | 5 × 108 – 5 × 109 CFU |
Multi- species/strain (n = 17) | 2 × 109–4.5 × 1010 CFU |
NPN | Probiotic Species Used (Strains if available) and Potency | Sport Specific Claims Supported by Research outside of monograph |
|---|---|---|
80,080,307 | B. breve BR03 5 Billion CFU S. salivarius ssp. thermophilus FP4 5 Billion CFU | Helps maintain gastrointestinal health which may assist in normal recovery of performance following exercise. |
80,077,863 | B. coagulans GBI-30, 6086 1 Billion CFU | B. coagulans GBI-30, 6086 could be used to improve symptoms of delayed onset muscle soreness (DOMS) after exercise. B. coagulans GBI-30, 6086 helps maintain gastrointestinal health which may assist in a normal recovery of performance following exercise. |
80,040,732 | L. helveticus 400 million CFU B. longum subsp. longum 600 million CFU | Helps maintain the health of the immune system following periods of physical stress. |
80,064,384 | L. helveticus 10 Billion CFU | Promotes gastrointestinal health in physically active adults Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress |
80,064,386 | L. helveticus 10 Billion CFU × 2 | Promotes GI health in physically active adults Helps support immune defenses against winter infections in healthy adults and in those having weakened immunity due to intensive sports activities Promotes GI health, immune health and general well-being in physically active adults (including sporty individuals like athletes) Reduces symptoms with upper respiratory tract infections Helps reduce incidence of cold-like symptoms in adults with exercise-induced stress With 20 Billion CFU per day, this product helps support the first line of body’s immune defenses (IgA production), which may be associated with lowering URTI risk in physically active adults (such as competitive athletes) |
80,050,736 | B. animalis subsp. lactis 23 Billion CFU B. animalis subsp. lactis 50 million CFU B. animalis subsp. lactis 1 Billion CFU B. bifidum 50 million CFU B. longum subsp. infantis 100 million CFU L. acidophilus 24.8 Billion CFU L. acidophilus 1 Billion CFU | Reduces the risk of developing upper respiratory tract illness in physically active adults Reduces the duration of URTI in physically active adults |
80,064,494 | B. animalis subsp. lactis BI-04 10 Billion CFU B. animalis subsp. lactis Bi-07 10 Billion CFU L. acidophilus NCFM 10 Billion CFU L. paracasei LPC-37 10 Billion CFU | Helps reduce the risk of developing URTI in physically active adults |
80,068,830 | B. animalis subsp. lactis Bi-04 2 Billion CFU | Reduces the risk of developing URTI in physically active adults Reduces the duration of URTI in physically active adults |
80,080,161 | B. longum subsp. longum 320 million CFU L. helveticus 2.68 billion CFU L. helveticus 5 Biillion CFU | Promotes GI health, immune health and general well-being in physically active adults (including sporty individuals like athletes) Reduces symptoms associated with upper-respiratory tract illness (URTI). Helps shorten the duration of URTI episodes Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress Helps support the first line of the body’s immune defenses (IgA production), which may be associated with lowering URTI risk in physically active adults (such as competitive athletes) Helps support immune defenses against winter infections in healthy adults and in those having weakened immunity due to intensive sports activities Helps to reduce gastrointestinal discomfort (e.g., abdominal pain, nausea, vomiting) in those experiencing mild to moderate stress resulting from life events (e.g., academic exams) Helps to moderate general feelings of anxiety Promotes a healthy mood balance Helps to reduce stress-related gastrointestinal complications such as abdominal pain |
80,089,514 | B. bifidum 3 Billion CFU L. helveticus 5 Billion CFU | Helps support immune defenses against winter infections in healthy adults and in those having weakened immunity due to intensive sports activities Helps to alleviate gastro-intestinal (GI) disturbances like flatulence, constipation, bloating and abdominal cramps in healthy adults Promotes GI health, immune health and general well-being in physically active adults (including sporty individuals like athletes) Reduces symptoms associated with upper-respiratory tract illness (URTI) Helps shorten the duration of URTI episodes Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress Helps support the first line of the body’s immune defenses (IgA production), which may be associated with lowering URTI risk in physically active adults (such as competitive athletes) Helps reduce the incidence of cold-like symptoms in stressed adults |
80,091,068 | B. animalis subsp. lactis 2 Billion CFU L. acidophilus 1 Billion CFU L. acidophilus 3 Billion CFU L. plantarum 14 Billion CFU | Reduces the risk of developing upper respiratory track illness in physically active adults Reduces the duration of upper respiratory tract illness in physically active adults |
80,091,070 | B. animalis subsp. lactis 2 Billion L. acidophilus 1 Billion L. acidophilus 3 Billion L. plantarum 14 Billion | Reduces the risk of developing upper respiratory track illness in physically active adults Reduces the duration of upper respiratory tract illness in physically active adults |
80,087,974 | B. animalis subsp. lactis 2.81 Billion CFU B. animalis subsp. lactis 1.47 Billion CFU B. animalis subsp. lactis 810 million CFU B. animalis subsp. lactis 530 million CFU B. bifidum 28 million CFU D-Glucose 13 mg D-Xylose 13 mg L-Arabinose 7 mg L. acidophilus 630 million CFU L. casei 610 million CFU L. paracasei 690 million CFU L. plantarum 890 million CFU L. salivarius 560 million CFU Xylooligosaccharides 631 mg | Reduces the risk of developing upper respiratory track illness in physically active adults Reduces the duration of upper respiratory tract illness in physically active adults |
Key Points 7 Regulation | |
• No universally agreed upon framework exists for regulating commercial products containing probiotics across countries globally. | |
• Probiotic products should be labelled in CFU, the scientifically accepted unit of measure for probiotics and used to report probiotic quantity in many studies conducted to assess the safety or benefits of probiotics. | |
• Dosing regimens typically fall in range between 1 × 109 to 1 × 1011 CFU. | |
• The IOC noted moderate support for probiotic use when administered for several weeks in athletes with a daily dose of 1 × 1010 CFU. | |
• Genera of commonly used probiotics include Lactobacillus (n = 35), Bifidobacterium (n = 18), Streptococcus (n = 8) and Bacillus (n = 5). | |
• Single-strain and multi- species/strain products are commonly used, but combinations and individual dosing recommendations are not currently understood | |
• Males and females may respond to probiotic supplementation differently. Future research is needed in this area. |
Future directions
Body composition and muscle mass
Buffering capacity in exercising muscles
Considerations for future study designs
Hormonal balance
Inactivated “probiotics”
Mood and cognition
Muscle damage and recovery
Neurotransmitter synthesis and release
Nutrient timing
Response to a physical or mental stressor
Key Points 8 – Future Directions | |
• Probiotic therapy has the potential to positively affect the endocrine system (testosterone production), especially for obese and/or aging athletes. | |
• Modulation of the gut microbiome could alter the production/level of important neurotransmitters related to athletic performance. | |
• Probiotic supplementation may have an impact on stress; however, current research is limited. | |
• Preliminary animal research suggests probiotic supplementation may support the removal and utilization of blood lactate. | |
• Important methodological considerations must be addressed systematically in future research including the effect of: sex, sample size, duration, dose (type and amount), level of physical activity, and type of exercise. |